Bio-Rad Sees Growth Trajectory for Droplet Digital PCR Despite Soft Q3 Life Science Segment Results | GenomeWeb

Bio-Rad Laboratories said last week that sales in its Life Science segment, which contains the company's PCR and digital PCR products, dropped 3 percent year over year and 1 percent on a currency-neutral basis.

Bio-Rad attributed the drop to continued slowness in the research spending environment, and noted that results were positively impacted by sales of antibodies and reagents from its January acquisition of AbD Serotec, as well as sales of biochromatography and cell-sorting instruments.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Science this week: Neanderthal-derived DNA linked to modern ailments, and more.

Japan needs to catch up on its gene-editing research efforts, the Japan News writes.

Hundreds of people have signed an online petition calling for zero tolerance to sexual harassment in the sciences.

Jeff Huber, former Google X senior vice president, joins Grail as its CEO.